Feedback
Settings

Settings

Goto Application

30,488 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

SDG-GoodHealth-Diabete-DE

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 3,049
1.WO/2004/028516COMPOSITIONS FOR THE INHIBITION OF PROTEIN KINASE C ALPHA FOR TREATMENT OF DIABETES MELLITUS AND CARDIOVASCULAR DISEASES
WO - 08.04.2004
Int.Class A61K 31/235
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
215of carboxylic acids
235having an aromatic ring attached to a carboxyl group
 Appl.No PCT/DE2003/003165 Applicant PHENOS GMBH Inventor MENNE, Jan
The invention relates to the use of agents impeding the expression and/or activity of protein kinase C alpha (PKC-), especially for treatment of patients with diabetes and complications such as diabetic nephropathy, retinopathy or neuropathy.
2.2338498Compositions for the inhibition of protein kinase C alpha for the treatment of diabetes mellitus
EP - 29.06.2011
Int.Class A61K 31/7088
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
 Appl.No 10170970 Applicant PHENOS GMBH Inventor MENNE JAN
Using an agent (A) that reduces or inhibits expression and/or activity of protein kinase Calpha (PKCa) for treatment and/or prevention of vascular and cardiovascular diseases, kidney diseases associated with proteinuria, long-term damage caused by diabetes and/or cardiovascular complications associated with diabetes mellitus, hypertension and/or hypercholesterolemia, is new. ACTIVITY : Cardiant; Vasotropic; Nephrotropic; Antidiabetic; Hypotensive; Antilipemic; Cerebroprotective; Ophthalmological; Neuroprotective. No biological data given. MECHANISM OF ACTION : Inhibiting expression and/or activity of PKCa, resulting in reduced expression of vascular endothelial growth factor (and of its receptor) in the kidney.
3.102013107025METHODEN UND ZUSAMMENSETZUNGEN ZUR BEHANLDUNG VON DIABETIS
DE - 03.07.2014
Int.Class A61K 31/122
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
12Ketones
122having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
 Appl.No 102013107025 Applicant Golden Biotechnology Corporation Inventor Liu Sheng-Yung

Die Erfindung stellt Verfahren und Zusammensetzungen zur Behandlung von Diabetes mit Cyclohexenonverbindungen zur Verfügung.

4.000010244453Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
DE - 01.04.2004
Int.Class A61K 45/
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
 Appl.No 10244453 Applicant PHENOMIQUES GMBH Inventor HALLER HERRMANN

Die vorliegende Erfindung betrifft die Verwendung von Agenzien, die die Expression und/oder Aktivität der Proteinkinase C-alpha (PKC-alpha) vermindern oder hemmen, zur Behandlung und/oder Prävention von koronarer Herzerkrankung, Herzinfarkt, peripherer Verschlusskrankheit, Schlaganfall, mit Proteinurie einhergehenden Nierenerkrankungen, diabetischen Spätschäden und/oder kardiovaskulären Komplikationen bei Patienten mit Diabetes mellitus, kardiovaskulären Komplikationen bei Patienten mit Hypertonus und kardiovaskulären Komplikationen bei Patienten mit Hypercholesterinämie.

5.000010319592Behandlung von diabetischer Retinopathie mit Angiotensin II-Rezeptorblockern
DE - 18.11.2004
Int.Class A61K 45/
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
 Appl.No 10319592 Applicant BOEHRINGER INGELHEIM PHARMA Inventor YAMAGISHI SHO-ICHI

Die Erfindung betrifft das Gebiet von Inhibitoren in Form von Angiotensin II-Rezeptorblockern und spricht insbesondere deren Verwendung in Diabetes an, um die Entwicklung oder das Fortschreiten von mikrovaskulärer Krankheit (d. h. Krankheit, welche die kleinen Blutgefäße betrifft), welche die Augen (diabetische Retinopathie) und Nieren (diabetische Nephropathie) beeinträchtigen, zu verhüten.

6.000060009777Verbindung für Behandlung und Vorsorge bei Diabetes
DE - 19.08.2004
Int.Class C07D 239/42
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
239Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
02not condensed with other rings
24having three or more double bonds between ring members or between ring members and non-ring members
28with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
32One oxygen, sulfur or nitrogen atom
42One nitrogen atom
 Appl.No 60009777 Applicant PFIZER PROD INC Inventor MYLARI BANAVARA LAKSHMAN
7.1545560COMPOSITIONS FOR INHIBITING PROTEIN KINASE C ALPHA FOR THE TREATMENT OF DIABETES MELLITUS
EP - 29.06.2005
Int.Class A61K 31/7088
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
 Appl.No 03770876 Applicant PHENOS GMBH Inventor MENNE JAN
Using an agent (A) that reduces or inhibits expression and/or activity of protein kinase Calpha (PKCa) for treatment and/or prevention of vascular and cardiovascular diseases, kidney diseases associated with proteinuria, long-term damage caused by diabetes and/or cardiovascular complications associated with diabetes mellitus, hypertension and/or hypercholesterolemia, is new. ACTIVITY : Cardiant; Vasotropic; Nephrotropic; Antidiabetic; Hypotensive; Antilipemic; Cerebroprotective; Ophthalmological; Neuroprotective. No biological data given. MECHANISM OF ACTION : Inhibiting expression and/or activity of PKCa, resulting in reduced expression of vascular endothelial growth factor (and of its receptor) in the kidney.
8.WO/2008/055491DIAGNOSIS AND RISK ASSESSMENT OF PANCREATIC DIABETES USING MR-PROADM
WO - 15.05.2008
Int.Class G01N 33/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
 Appl.No PCT/DE2007/002018 Applicant BRAHMS AKTIENGESELLSCHAFT Inventor BERGMANN, Andreas
The invention relates to a method for diagnosis and/or risk assessment of pancreatic diabetes, in particular of diabetic sequelae, wherein a determination of the marker mid-regional proAdrenomedullin (MR-proADM: SEQ ID No. 2) or a partial peptide or fragment thereof or if contained in a marker combination (Panel, Cluster) is carried out on a patient under investigation. The invention further relates to a diagnostic device and a kit for carrying out said method.
9.202025100327System zur kontinuierlichen Glukoseüberwachung und Echtzeit-Vorhersage zum Diabetes-Management
DE - 20.03.2025
Int.Class G16H 50/30
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
30for calculating health indices; for individual health risk assessment
 Appl.No 202025100327 Applicant Patil Sachin Chandrakant Inventor

Ein System zur kontinuierlichen Glukoseüberwachung und Echtzeit-Vorhersage zur Diabetesbehandlung, umfassend: ein Netzwerk nicht-invasiver Glukosesensoren, entwickelt mit biokompatiblen Materialien und Sensortechnologie, die am Körper platziert sind, um kontinuierlich Glukosewerte zu messen, ohne Unbehagen oder invasive Verfahren zu verursachen; eine zentrale Verarbeitungseinheit, die eine KI-gesteuerte Analyseplattform enthält, welche die drahtlos von den Glukosesensoren übermittelten Daten empfängt und verarbeitet; eine KI-gesteuerte Analyseplattform, konfiguriert zur Durchführung von Deep-Learning- und Machine-Learning-Aufgaben, um Daten zu analysieren und zukünftige Glukoseschwankungen vorherzusagen.

10.102006052916Diagnose und Risikostratifizierung von Diabetes mellitus mittels MR-proADM
DE - 15.05.2008
Int.Class G01N 33/68
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
 Appl.No 102006052916 Applicant BRAHMS AG Inventor BERGMANN ANDREAS

Die Erfindung betrifft ein Verfahren zur Diagnose und/oder Risikostratifizierung von Diabetes mellitus, insbesondere von diabetischen Folgeerkrankungen, wobei eine Bestimmung des Markers midregionalem proArenomedullin (MR-proADM: SEQ ID No. 2) oder ein Teilpeptid oder Fragment davon oder enthaltend in einer Markerkombination (Panel, Cluster) an einem zu untersuchenden Patienten durchgeführt wird. Weiterhin betrifft die Erfindung eine diagnostische Vorrichtung und ein Kit zur Durchführung des Verfahrens.

# -